ICS/LABA

Phase 3Small molecule

Regeneron

ICS/LABA is one of 27 small molecule programs targeting Asthma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaUnknown status

AsthmaPhase 3

Unknown status

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

ICS/LABA

Regeneron

Phase 3

5 2

Celexa

AbbVie

Preclinical

1 3

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

DUPIXENT

Regeneron

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

Aclidinium Bromide

Atrovent

2 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Asthma

NCT07272278

Post-ApprovalRecruiting

Asthma

NCT06572228

Clinical

Trials by Indication[1]

Asthma5 trials

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Recruiting· Regeneron logo

Regeneron·Phase 4·NCT06572228·250 enrolled

Azithromycin Treatment for Non-eosinophilic Chest Tightness Variant Asthma

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05596721·248 enrolled

Prospective Clinical Study on the Clinical Efficacy and Prognostic Outcome of ICS/LABA Combined With Liqin Zhike Formula in the Treatment of Cough Variant Asthma

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07272278·236 enrolled

Show 2 more trials

Oral Intake of Mg in Controlled Asthmatic Patients

Active, not recruiting·ZZagazig University·Phase 2/3·NCT06721247·166 enrolled

Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma

Unknown status·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 4·NCT01404013·99 enrolled

Cystic Fibrosis1 trial

Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis

Completed·SShanghai Pulmonary Hospital, Shanghai, China·Phase 4·NCT02782312·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for ICS/LABA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ICS/LABA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ICS/LABA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Regeneron

ICS/LABA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Asthma5 trials

Cystic Fibrosis1 trial

References

Drug Info

Quick Facts

Related News